Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) closed at $25.29 down -5.56% from its previous closing price of $26.78. In other words, the price has decreased by -$5.56 from its previous closing price. On the day, 1.08 million shares were traded. TNXP stock price reached its highest trading level at $27.27 during the session, while it also had its lowest trading level at $25.18.
Ratios:
For a deeper understanding of Tonix Pharmaceuticals Holding Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.22 and its Current Ratio is at 7.53. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4. ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 21 ’25 when Taylor Carolyn E. bought 418 shares for $36.03 per share. The transaction valued at 15,061 led to the insider holds 418 shares of the business.
Treco James bought 250 shares of TNXP for $9,000 on Aug 20 ’25. The Director now owns 250 shares after completing the transaction at $36.00 per share. On May 15 ’25, another insider, LEDERMAN SETH, who serves as the Chief Executive Officer of the company, bought 4,000 shares for $21.55 each. As a result, the insider paid 86,200 and bolstered with 4,005 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNXP now has a Market Capitalization of 221689520 and an Enterprise Value of 96850512. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.55 while its Price-to-Book (P/B) ratio in mrq is 1.14. Its current Enterprise Value per Revenue stands at 9.852 whereas that against EBITDA is -1.212.
Stock Price History:
The Beta on a monthly basis for TNXP is 1.90, which has changed by 0.9453846 over the last 52 weeks, in comparison to a change of 0.16333759 over the same period for the S&P500. Over the past 52 weeks, TNXP has reached a high of $130.00, while it has fallen to a 52-week low of $6.76. The 50-Day Moving Average of the stock is -33.79%, while the 200-Day Moving Average is calculated to be -11.45%.
Shares Statistics:
For the past three months, TNXP has traded an average of 1.47M shares per day and 1300580 over the past ten days. A total of 8.77M shares are outstanding, with a floating share count of 8.76M. Insiders hold about 0.08% of the company’s shares, while institutions hold 15.97% stake in the company. Shares short for TNXP as of 1756425600 were 1173859 with a Short Ratio of 0.80, compared to 1753920000 on 1206311. Therefore, it implies a Short% of Shares Outstanding of 1173859 and a Short% of Float of 13.389999999999999.
Earnings Estimates
Tonix Pharmaceuticals Holding Corp (TNXP) is currently under the scrutiny of 1.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$3.05, with high estimates of -$3.05 and low estimates of -$3.05.
Analysts are recommending an EPS of between -$10.3 and -$10.3 for the fiscal current year, implying an average EPS of -$10.3. EPS for the following year is -$4.5, with 1.0 analysts recommending between -$4.5 and -$4.5.
Revenue Estimates
A total of 2 analysts believe the company’s revenue will be $2.3M this quarter.It ranges from a high estimate of $2.5M to a low estimate of $2.1M. As of the current estimate, Tonix Pharmaceuticals Holding Corp’s year-ago sales were $2.82MFor the next quarter, 2 analysts are estimating revenue of $2.9M. There is a high estimate of $3.6M for the next quarter, whereas the lowest estimate is $2.2M.
A total of 2 analysts have provided revenue estimates for TNXP’s current fiscal year. The highest revenue estimate was $10.5M, while the lowest revenue estimate was $8.7M, resulting in an average revenue estimate of $9.6M. In the same quarter a year ago, actual revenue was $10.09MBased on 3 analysts’ estimates, the company’s revenue will be $94.17M in the next fiscal year. The high estimate is $203.5M and the low estimate is $31.3M.
